Description
Product Usage Information
SM-164 is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 1 mg of powder in 89 μL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Background
SM-164 is a bivalent, cell-permeable, non-peptide, SMAC mimetic and potent XIAP inhibitor with an IC value of 1.39 nM. SM-164 binds to the BIR2 and BIR3 domains of XIAP and effectively inhibits cell growth and induces apoptosis in HL-60 leukemia cells (1). It also activates caspase-3 and caspase-9 that, in turn, induce apoptosis in leukemia cells (1,2). In breast cancer mouse xenograft models, SM-164 in combination with TNF-related apoptosis-inducing ligand (TRAIL) has been shown to reduce tumor volume by 80%. SM-164 is an effective apoptotic inducer of tumor cells and tissues and is a promising candidate for a new class of anticancer drugs (2). Treatment of RIP3-positive cells with SM-164 in combination with TNF-alpha and the caspase inhibitor Z-VAD, leads to necroptosis (3).
Alternate Names
(3S,3â²S,6S,6â²S,10aS,10â²aS)-N,Nâ²-[1,4-phenylenebis[4,1-butanediyl-1H-1,2,3-triazole-1,4- diyl[(S)-phenylmethylene]]]bis[decahydro-6-[[(2S)-2-(methylamino)-1-oxopropyl]amino]-5- oxo-pyrrolo[1,2-a]azocine-3-carboxamide
